ProCE Banner Activity

My Thoughts on the Latest Developments in Small-cell Lung Cancer From ASCO 2019

Clinical Thought
Here are my thoughts on a few studies presented at ASCO 2019 with the potential to impact SCLC care in the near future.

Released: June 25, 2019

Expiration: June 23, 2020

No longer available for credit.

Share

Faculty

Taofeek K. Owonikoko

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech TEXT Only

Faculty Disclosure

Primary Author

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Taofeek K. Owonikoko, MD, PhD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aeglea BioTherapeutics, Amgen, Astellas, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, Celgene, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo Oncology/Lilly, Merck, Novartis, Pfizer, Regeneron, Stemcentrx, and United Therapeutics; has received consulting fees from AbbVie, Amgen, ARMO BioSciences, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Therapeutics, Lilly, MedImmune, Novartis, PharmaMar, Sandoz, Seattle Genetics, Takeda, and Xcovery; has received fees for non-CME/CE services from EMD Serono and Roche/Genentech; and has ownership interest in Cambium Oncology.